정신의학에서 대마 관련 약물의 전망

키워드

참고문헌 (78)

1. World drug report 2019. Booklet 5: cannabis and hallucinogens, "United Nations Office on Drugs and Crime", United Nations Office on Drugs and Crime, ~ (2019)
2. "UNODC.org" (2021)[URL]
3. Testai FD, "Use of marijuana : effect on brain health : a scientific statement from the American Heart Association", Stroke, 53, pp.e176~e187 (2022)
4. Ganesh S, "Cannabis and psychosis : recent epidemiological findings continuing the"causality debate"", Am J Psychiatry, 179, pp.8~10 (2022)
5. Fischer B, "Cannabis use, legalization and youth health", CMAJ, 189, pp.E971~E972 (2017)
6. "Edition.CNN.com" (2018)[URL]
7. Hasin DS, "US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws : 1991-1992 to 2012-2013", JAMA Psychiatry, 74, pp.579~588 (2017)
8. Mechoulam R, "The endocannabinoid system and the brain", Annu Rev Psychol, 64, pp.21~47 (2013)
9. Scopetti M, "Cannabinoids and brain damage : a systematic review on a frequently overlooked issue", Curr Pharm Biotechnol, 24, pp.741~757 (2023)
10. Gaoni Y, "Isolation, structure, and partial synthesis of an active constituent of hashish", J Am Chem Soc, 86, pp.1646~1647 (1964)
11. Moffat AC, "Clarke’s analysis of drugs and poisons" (2011), Pharmaceutical Press
12. Munro S, "Molecular characterization of a peripheral receptor for cannabinoids", Nature, 365, pp.61~65 (1993)
13. Hillard CJ, "Stress regulates endocannabinoid-CB1 receptor signaling", Semin Immunol, 26, pp.380~388 (2014)
14. Legare CA, "Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals", Pharmacology, 107, pp.131~149 (2022)
15. Hill MN, "The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses", Psychol Med
16. D’Souza DC, "The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals : implications for psychosis", Neuropsychopharmacology, 29, pp.1558~1572 (2004)
17. Rey AA, "Biphasic effects of cannabinoids in anxiety responses : CB1 and GABA(B)receptors in the balance of GABAergic and glutamatergic neurotransmission", Neuropsychopharmacology, 37, pp.2624~2634 (2012)
18. Iffland K, "An update on safety and side effects of cannabidiol : a review of clinical data and relevant animal studies", Cannabis Cannabinoid Res, 2, pp.139~154 (2017)
19. Sylantyev S, "Cannabinoid-and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses", Proc Natl Acad Sci U S A, 110, pp.5193~5198 (2013)
20. Andréasson S, "Cannabis and schizophrenia. A longitudinal study of Swedish conscripts", Lancet, 2, pp.1483~1486 (1987)
21. Strang J, "Improving the quality of the cannabis debate : defining the different domains", BMJ, 320, pp.108~110 (2000)
22. Silva PA, "From child to adult : the Dunedin multidisciplinary health and development study" (1996), Oxford University Press
23. Arseneault L, "Cannabis use in adolescence and risk for adult psychosis : longitudinal prospective study", BMJ, 325, pp.1212~1213 (2002)
24. Dow-Edwards D, "Endocannabinoids in brain plasticity : cortical maturation, HPA axis function and behavior", Brain Res, 1654(Pt B), pp.157~164 (2017)
25. Hebert-Chatelain E, "A cannabinoid link between mitochondria and memory", Nature, 539, pp.555~559 (2016)
26. Crane NA, "Neuropsychological sex differences associated with age of initiated use among young adult cannabis users", J Clin Exp Neuropsychol, 37, pp.389~401 (2015)
27. Cloak CC, "Psychiatric symptoms, salivary cortisol and cytokine levels in young marijuana users", J Neuroimmune Pharmacol, 10, pp.380~390 (2015)
28. Wilkinson ST, "Impact of cannabis use on the development of psychotic disorders", Curr Addict Rep, 1, pp.115~128 (2014)
29. D’Souza DC, "Cannabinoids and psychosis", Curr Pharm Des, 22, pp.6380~6391 (2016)
30. Ganesh S, "Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol : a mega analysis of individual participant-data from human laboratory studies", Int J Neuropsychopharmacol, 23, pp.559~570 (2020)
31. Hindley G, "Psychiatric symptoms caused by cannabis constituents : a systematic review and meta-analysis", Lancet Psychiatry, 7, pp.344~353 (2020)
32. Food and Drug Administration, "Marinol®" (2004), Food and Drug Administration
33. European Medicines Agency, "Acomplia" (2009), European Medicines Agency
34. Electronic Medicines Compendium, "Sativex oromucosal spray" (2015), Electronic Medicines Compendium
35. "Epidiolex.com" (2018)[URL]
36. "Fda.gov" (2018)[URL]
37. National Academy of Medicine of Korea, "2021 guidance for prevention of meical marjuana abuse for general public" (2021), National Academy of Medicine of Korea
38. Graczyk M, "Prospects for the use of cannabinoids in psychiatric disorders", Front Psychiatry, 12, pp.620073~ (2021)
39. Rutkowska M, "Effects of cannabinoids on the anxiety-like response in mice", Pharmacol Rep, 58, pp.200~206 (2006)
40. Naderi N, "Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice", Pharmacol Biochem Behav, 89, pp.64~75 (2008)
41. Bergamaschi MM, "Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients", Neuropsychopharmacology, 36, pp.1219~1226 (2011)
42. Bhattacharyya S, "Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1(CB1)receptors", Sci Rep, 7, pp.15025~ (2017)
43. Black N, "Cannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis", Lancet Psychiatry, 6, pp.995~1010 (2019)
44. Kwee CMB, "Anxiolytic effects of endocannabinoid enhancing compounds : a systematic review and meta-analysis", Eur Neuropsychopharmacol, 72, pp.79~94 (2023)
45. Whiting PF, "Cannabinoids for medical use : a systematic review and meta-analysis", JAMA, 313, pp.2456~2473 (2015)
46. Bisson JI, "Post-traumatic stress disorder", BMJ, 351, pp.h6161~ (2015)
47. Betthauser K, "Use and effects of cannabinoids in military veterans with posttraumatic stress disorder", Am J Health Syst Pharm, 72, pp.1279~1284 (2015)
48. Jetly R, "The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares : a preliminary randomized, double-blind, placebo-controlled cross-over design study", Psychoneuroendocrinology, 51, pp.585~588 (2015)
49. Corroon J, "A cross-sectional study of cannabidiol users", Cannabis Cannabinoid Res, 3, pp.152~161 (2018)
50. Moltke J, "Reasons for cannabidiol use : a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems", J Cannabis Res, 3, pp.5~ (2021)
51. Monti JM, "Hypnoticlike effects of cannabidiol in the rat", Psychopharmacology(Berl), 55, pp.263~265 (1977)
52. Murillo-Rodríguez E, "Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats", FEBS Lett, 580, pp.4337~4345 (2006)
53. Chagas MH, "Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats", J Psychopharmacol, 27, pp.312~316 (2013)
54. Murillo-Rodríguez E, "Sleep-wake cycle disturbances and NeuN-altered expression in adult rats after cannabidiol treatments during adolescence", Psychopharmacology(Berl), 238, pp.1437~1447 (2021)
55. Bartoli F, "Cannabidiol for mood disorders : a call for more research", Can J Psychiatry, 66, pp.182~183 (2021)
56. Bartoli F, "Efficacy of cannabidiol for Δ-9-tetrahydrocannabinol-induced psychotic symptoms, schizophrenia, and cannabis use disorders : a narrative review", J Clin Med, 10, pp.1303~ (2021)
57. Rosic T, "The association between cannabis use and outcome in pharmacological treatment for opioid use disorder", Harm Reduct J, 18, pp.24~ (2021)
58. Hurd YL, "Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder : a double-blind randomized placebo-controlled trial", Am J Psychiatry, 176, pp.911~922 (2019)
59. Kalia LV, "Parkinson’s disease", Lancet, 386, pp.896~912 (2015)
60. Thanabalasingam SJ, "Cannabis and its derivatives for the use of motor symptoms in Parkinson’s disease : a systematic review and meta-analysis", Ther Adv Neurol Disord, 14, pp.17562864211018561~ (2021)
61. Ross CA, "Huntington’s disease : from molecular pathogenesis to clinical treatment", Lancet Neurol, 10, pp.83~98 (2011)
62. Gövert F, "Huntington’s disease and Huntington’s disease-like syndromes : an overview", Curr Opin Neurol, 26, pp.420~427 (2013)
63. Hillard CJ, "The endocannabinoid signaling system in the CNS : a primer", Int Rev Neurobiol, 125, pp.1~47 (2015)
64. MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users, "Addict Biol", 2015, 357~367
65. Sideli L, "Cannabis use and the risk for psychosis and affective disorders", J Dual Diagn, 16, pp.22~42 (2020)
66. Cravatt BF, "Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides", Nature, 384, pp.83~87 (1996)
67. deRoon-Cassini TA, "Meet your stress management professionals : the endocannabinoids", Trends Mol Med, 26, pp.953~968 (2020)
68. "Drugfree.or.kr" (2018)[URL]
69. "UNODC.org" (2018)[URL]
70. Giroud C, "E-cigarettes : a review of new trends in cannabis use", Int J Environ Res Public Health, 12, pp.9988~10008 (2015)
71. Hill KP, "Risks and benefits of cannabis and cannabinoids in psychiatry", Am J Psychiatry, 179, pp.98~109 (2022)
72. Hasin DS, "US epidemiology of cannabis use and associated problems", Neuropsychopharmacology, 43, pp.195~212 (2018)
73. De Aquino JP, "The psychiatric consequences of cannabinoids", Clin Ther, 40, pp.1448~1456 (2018)
74. Hill M, "Perspective : be clear about the real risks", Nature, 525, pp.S14~ (2015)
75. Key substance use and mental health indicators in the United States: results from the 2019 national survey on drug use and health (HHS publication no. PEP20-07-01-001, NSDUH series H-55), "Substance Abuse and Mental Health Services Administration", Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, ~ (2020)
76. Park JY, "Prevalence, reasons, perceived effects, and correlates of medical marijuana use : a review", Drug Alcohol Depend, 177, pp.1~13 (2017)
77. 19), "Cannabis-based medicinal products(position statement PS05", pp.2019, Royal College of Psychiatrists
78. Vinod N, "Regulation of appetite for treating obesity : lessons from the rimonabant debacle", Curr Trends Biomedical Eng Biosci, 15, pp.555908~ (2018)

관련 논문AI추천